Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 6Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Nasopharyngeal Carcinoma 2Squamous NSCLC 1Squamous Cell Non-small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Resectable Non-small Cell Lung Cancer 1Radiation Pneumonitis 1Non-Squamous Non-Small Cell Lung Cancer 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1MSI-H 1Lung Neoplasms 1HER2+ Breast Cancer 1Gastrointestinal Diseases 1Esophageal Diseases 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Advanced Non-squamous Non-Small-Cell Lung Cancer 1

Interventions

spartalizumab 1sintilimab 1Nivolumab 1Docetaxel 1Carboplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Squamous Cell Non-small Cell Lung Cancer × sintilimab × Clear all
NCT05429463 2022-12-14

neoSCORE â…¡

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 3 Recruiting
250 enrolled
Thoracic

Squamous Cell Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡